A synthetic peptide that stimulates your skin to produce more melanin (giving you a tan without UV exposure), suppresses appetite, and boosts libido. Basically a tanning, fat-loss, and sexual function peptide rolled into one.
What to Expect
Week 1–2
Nausea common on first doses. Facial flushing. Skin darkening begins within days. Appetite suppression. Possible spontaneous erections.
Week 3–6
Significant skin tanning without UV exposure. Sustained appetite suppression. Increased libido. Moles and freckles may darken.
Week 8+
Maximum tanning effect reached. Transition to maintenance dosing. Long-term mole monitoring important.
Common Side Effects
Dosing
Loading: 250-500 mcg daily for 2 weeks. Maintenance: 250 mcg once or twice a week.
Practical Guide
Reconstitution
Mix 10mg vial with 2mL BAC water. Loading dose: 250-500mcg. Maintenance: 500mcg 1-2x/week.
Storage
Refrigerate after reconstitution. Use within 30 days. Protect from light.
Injection Sites
Subcutaneous with insulin syringe. Start with very low dose (100mcg) to assess nausea tolerance. Anti-nausea medication may help initially.
Timing
Evening dosing — nausea and flushing easier to manage while sleeping. Tanning effects occur with or without UV exposure.
Food
Inject on empty stomach to reduce nausea. Have anti-nausea medication available for first doses.
Benefit Profile
Medical Considerations
Contraindications
- ✕Pregnancy/nursing
- ✕History of melanoma or atypical moles
- ✕Cardiovascular disease
- ✕Autoimmune conditions
Drug Interactions
Recommended Monitoring
- →Full body mole check before starting and every 3 months
- →Blood pressure monitoring
- →Watch for mole changes, asymmetry, or new growths
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Role of Temozolomide Regimen on Survival Outcomes in Molecularly Stratified WHO Grade II Gliomas: A Systematic Review.
Melanotan II: a possible cause of renal infarction: review of the literature and case report.
Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review.
Melanotan-induced priapism: a hard-earned tan.
Metallothionein in Brain Disorders.
Protective role of metallothionein in chemical and radiation carcinogenesis.
A review of metallothionein isoforms and their role in pathophysiology.
Discovery and development of novel melanogenic drugs. Melanotan-I and -II.